-
Citi Downgrades Intercept, Says NASH Launch Is Appropriately Priced In
Thursday, January 2, 2020 - 1:40pm | 342Read More...Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT), which is considered the frontrunner in the race for a non-alcoholic steatohepatitis, or NASH, drug, are fairly valued at current levels, according to an analyst at Citigroup. The Analyst Joel Beatty downgraded Intercept from Buy to Neutral and...
-
Citi: Solid Biosciences Rally Unsupported By Fundamentals
Thursday, August 29, 2019 - 11:38am | 426Read More...Following the near 100% rally in shares of Solid Biosciences Inc (NASDAQ: SLDB) in August, one Citigroup analyst said the stock price is diverging from worsening fundamentals. The Analyst Joel Beatty downgraded Solid Biosciences from Neutral to Sell and maintained a $6 price target. The...
-
Citi Downgrades Esperion As Hope Of Acquisition Dwindles
Monday, January 22, 2018 - 10:58am | 391Read More...Esperion Therapeutics Inc (NASDAQ: ESPR) is finishing research on its bemepedoic acid for lipid management, and while the Street expects success, the drug’s potential is weighted by a dearth of interested buyers. The Rating Citi analyst Joel Beatty downgraded Esperion to Neutral, but raised...
-
More Bad News For Novavax: A Citi Downgrade
Tuesday, December 19, 2017 - 10:48am | 399Read More...Novavax, Inc. (NASDAQ: NVAX), a small-cap clinical-stage vaccine company that focuses on therapies for both known and newly emerging diseases, has lost some support from a Wall Street analyst. The Analyst Citi's Joel Beatty downgraded Novavax's stock from Buy to Neutral. The Thesis...
-
Novavax The Downtrodden Finally Finds A New Bull At Citi
Tuesday, October 31, 2017 - 10:00am | 459Read More...Analysts at Citi turned bullish on Novavax, Inc. (NASDAQ: NVAX), a small-cap clinical-stage vaccine company. The firm's Joel Beatty upgrades Novavax's stock rating from Neutral to Buy with a price target boosted from $1.10 to $1.60. Novavax's phase 1 and phase 2 data for its flu vaccine called...
-
The Search For Silver Linings In The Cloud Of Negative Novavax News
Monday, September 19, 2016 - 11:35am | 497Read More...It’s hard to find a silver lining following news that sends a stock crashing 84.5 percent in one day. However, following devastating news that the Phase III RESOLVE trial of its RSV vaccine failed to deliver the desired results, Novavax, Inc. (NASDAQ: NVAX) shareholders are looking for any...
-
Citi Cuts Novavax's Price Target From $12 To $1.50 Following Failed Trial
Friday, September 16, 2016 - 7:50am | 301Read More...Following disappointing Phase 3 results for the RSV vaccine in older adults, Novavax, Inc. (NASDAQ: NVAX) reported mixed results for a Phase 2 trial of the vaccine on older adults who were reimmunized. Citi’s Joel Beatty downgraded the rating on the company from Buy to Neutral, while...
-
Citigroup Downgrades Raptor Pharma; Concerned With Declining Investor Sentiment Around Revenue
Monday, August 8, 2016 - 8:06am | 265Read More...Raptor Pharmaceutical Corp. (NASDAQ: RPTP) reported its 2Q16 revenue ahead of expectations. Citi’s Joel Beatty downgraded the rating on the company from Buy to Neutral, citing elevated investor expectations around revenue. The price target has been raised from $6 to $8. Results And...
-
Esperion Price Target Cut At Citi On U.S. Approval Likelihood
Thursday, June 30, 2016 - 7:10am | 222Read More...Esperion Therapeutics Inc (NASDAQ: ESPR) announced that the FDA had not agreed to LDL as an approvable surrogate endpoint for the company’s cholesterol agent bempedoic acid. Citi’s Joel Beatty maintained a Buy rating on the company, while reducing the price target from $36 to $22. The...
-
These Analysts Like Syndax's Breast Cancer Drug
Monday, March 28, 2016 - 8:39am | 498Read More...Morgan Stanley’s Matthew Harrison initiated coverage of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with an Overweight rating and price target of $22, while Citi’s Joel Beatty also initiated coverage of the company with a Buy rating and price target of $24. Major Value Driver Both...
-
Citi Downgrades PTC Therapeutics Following Major Setback
Wednesday, February 24, 2016 - 9:06am | 265Read More...Citi's Joel Beatty downgraded the rating on PTC Therapeutics, Inc. (NASDAQ: PTCT) from Buy to Neutral, while lowering the price target from $90 to $13. The downgrade follows the company's announcement on February 23 that the FDA has refused to review the Translarna application in the...
-
Citi Sees Limited Sales For Blood-Clot Drug At The Medicines Company
Thursday, April 16, 2015 - 4:35pm | 167Read More...The Medicines Company (NASDAQ: MDCO)'s blood-clot prevention drug will serve as a last-line treatment with limited sales, an analyst said Thursday. A Food and Drug Administration advisory panel on Wednesday recommended the company's cangrelor as a treatment for certain heart-surgery patents. But...
